129 results about "Lysin" patented technology

The present invention relates to a lysin protein originated from bacteriophage, more precisely a lysin protein comprising the amino acid sequence represented by SEQ. ID. NO: 2 which has no harm to human and animals comprising eukaryotic cells owing to its specificity to bacteria and has broad antibacterial activity, and a pharmaceutical composition for the prevention and treatment of infectious disease caused by bacteria comprising the said lysin protein as an active ingredient.

The present invention provides a reagent for cancer cell detection or cancer diagnosis. The present invention relates to a reagent for cancer cell detection, comprising a recombinant virus where a replication cassette comprising a promoter from human telomerase, an E1A gene, an IRES sequence and an E1B gene in this order is integrated in E1 region of the viral genome and a labeling cassette comprising a gene encoding a labeling protein and a promoter capable of regulating the expression of the gene encoding the labeling protein is integrated in E3 region of the viral genome.

The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).

The present invention relates to virulent (lytic) Listeria monocytogenes phage from the Myoviridae family, preferably P100, alone or in combination with other virulent phages. P100 and the endolysin from P100 can be administered to food products, to the components that will be added to food products, and / or to the infrastructure of the food processing plants within which such food products are processed, or the containers or wraps in which such foods are stored and / or shipped, in order to reduce Listeria monocytogenes contamination. P100 can also be used in the present invention to identify Listeria monocytogenes bacteria present on (or within) foodstuffs, as well as those Listeria monocytogenes bacteria present in the equipment or the general environment of the food processing plants in which the foodstuffs are being processed and in animals infected with Listeria monocytogenes. The phage and the endolysin of the present invention can also be used to treat animals infected with Listeria monocytogenes. P100 will kill the bacteria that are within its host range with great efficiency and will propagate to high titer thereon. P100 can be combined with other lytic phage, and / or with other antimicrobial agents to reduce or eliminate Listeria.

The present invention features therapeutic bacteriophage deficient in the lysin protein (“Lys minus” phage). Lys minus bacteriophage are incapable of facilitating efficient lysis of the bacterial host since the enzymatic activity of the lysin of the phage is needed for breaking down the peptidoglycan layer of the bacterial cell wall. Lys minus bacteriophage retain activity in invasion of its appropriate bacterial host, destruction of the bacterial genome, and replication, which are sufficient to inhibit bacterial growth and replication. Therefore, the therapeutic Lys minus phage stops the spread of infection by the bacterial pathogen without lysis of the bacterium. This approach is attractive as it also prevents the release of the phage progeny, thus reducing or eliminating the potential for generation of immune responses against the phage. The incapacitated bacterial pathogen is then removed by the normal defense systems such as phagocytes and macrophages.

Granulysin peptides are small antimicrobial agents with potent activity. A pharmaceutical composition comprising granulysin peptides as an active agent is administered therapeutically to a patient for exfoliation, e.g. for the treatment of skin lesions.

The invention features incapacitated whole cell bacterial immunogenic compositions produced by infecting a bacterium with Lys minus bacteriophage, which are deficient in the lysin protein. Lys minus bacteriophage retain activity in infection of its appropriate bacterial host, destruction of the bacterial genome, and replication, which are sufficient to inhibit bacterial growth and replication. The resulting, Lys minus-infected bacterium is provided in a state of bacteriostasis, and is not capable of replicating further (e.g., is “incapacitated”). The incapacitated bacterium can then be used as to elicit an immune response for prophylactic and / or therapeutic purposes. The invention thus also features incapacitated bacteria formulated appropriately for use in immunogenic compositions for eliciting an immune response, e.g., for production of antibodies in a non-human host or in a whole cell bacterial vaccine.

A nucleic acid comprising a nucleotide sequence encoding a lysin, which nucleotide sequence comprises the sequence shown in SEQ IDNo. 1 or a variant, homologue or derivative thereof. A novel lysin obtainable from a bacteriophage capable of colonising Clostridium perfringens, and the use thereof as a medicament for the treatment of a disorder associated with pathogenic Clostridium bacteria, for example.

The present invention provides a reliable method to determine lysin of ferrohemoglobin, and meanwhile white cell can be divided into two subgroups for counted separately. How to use the lisin is also included in the present invention. The lysin with no cyanide includes at least one type of surfactant group dissolve red cell sufficiently and to release magnitude of magnitude ferrohemoglobin, at least one type of positive ion surfactant, at least one type of negative ion surfactant and at least one type of non-ion surfactant.

The present invention provides isolated polypeptides comprising the amino acid sequence of SEQ ID NO:1, or a fragment, variant, derivative or fusion thereof which is capable of binding specifically to and / or lysing cells of Clostridium difficile, and means for producing the same, with the proviso that the fragment, variant, derivative or fusion is not a naturally occurring lysin of a bacteriophage of Clostridium difficile. The invention further provides methods for killing bacterial cells, such as cells of Clostridium difficile, and for diagnosing, treating and preventing diseases and conditions associated with infection of the same. The invention also provides diagnostic kits for use in such methods.

The T cell activation marker, granulysin, is demonstrated to be an effective antimicrobial agent. It is used in vitro and in vivo to reduce the population of viable cells in a microbial population. Of particular interest is the use of the active fragment of human granulysin, or modified forms thereof, to treat bacterial infections.

The invention discloses a telomere length detecting method based on a biological nano channel of aerolysin. The method comprises the following steps: (1) opening the G-quadruplet structure of telomere DNA of human; (2) preparing a biological nano channel of aerolysin: (a) activating aerolysin; (b) preparing a phospholipid n-decane solution; (c) preparing phospholipid bilayer; (d) forming a biological nano channel of aerolysin; (3) using the biological nano channel of aerolysin to detect the telomere length: (a) collecting monomolecular signal data; (2) analyzing the monomolecular signal data. Compared with the prior art, the provided method has the advantages that the operation is simple and efficient; enzyme digestion, molecular hybridization, or fluorescence labeling is not needed; the consumption of DNA substrate is little; the detection sensitivity and resolution are high; the price is cheap; the absolute length of telomere can be precisely and directly measured in real time; and the method has a positive meaning for bioscience research.

The invention relates to the filed of molecular biology, in particular to cynoglossus semilaevis natural killer (NK)-lysin and application method of the cynoglossus semilaevis NK-lysin. NK-lysin is as the display of an amino acid sequence in sequencer (SEQ) ID No.1. The application method is that the cynoglossus semilaevis complementary deoxyribonucleic acid (c DNA) serves as a template, and a primer F1 and a primer R1 are utilized to carry out polymerase chain reaction (PCR) amplification. After a PCR product is connected with an expressive vector, plasmids (p CNK1) are obtained, the plasmids (p CNK1) are injected into fishes and the antiviral capacity and the antibacterial capacity of the fishes can be obviously intensified.

The present invention relates to chimeric polypeptides comprising a first portion, which comprises a bacteriocin cell wall-binding domain (CBD) and a second portion, which comprises an enzymatic active domain (EAD) selected from the lytic domain of a bacteriophage lysin, a bacteriocin and a bacterial autolysin. Provided are such chimeric polypeptides and variants and fragments thereof, nucleic acids encoding the same, vectors carrying such nucleic acids and host cells transformed or transfected with such vectors. The chimeric polypeptides of the present invention are useful for the reduction of certain bacterial populations, including methods and compositions for the treatment of various bacterial infections. For example, chimeric polypeptides of the present invention have been shown to effectively kill various bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), as well as other human pathogens. Thus, provided are compositions comprising chimeric polypeptides according to the present invention, variants or fragments thereof, and the use of such compositions in prophylaxis or therapy of bacterial diseases, bacterial infections or bacterial colonisations.

The invention relates to a carrier capable of showing and expressing a heterologous gene on the surface of lactococcus lactis, and a preparation method and application of the carrier. The carrier has the nucleotide sequence which is shown as SEQ ID NO.1 in a sequence table, and contains promoter Pnis and lysM genes, a signal peptide secretion sequence ssusp45, a multiple cloning endonuclease site, and replicon repA and repC components. A method for constructing the carrier has the following steps of: amplifying a lactococcus lactis NZ3900 strain autolysin (AcmA) anchoring area gene lysM by applying a polymerase chain reaction (PCR) technology, performing enzyme digestion on the lysM and a carrier pNZ8110 and connecting, wherein a connection product is used for transforming a E.coli MC1061 strain, and extracting recombinant plasmid from positive transformed bacteria which are subjected to enzyme digestion and sequencing identification to obtain the expression carrier. The exogenous gene and the carrier are connected and then transferred into lactococcus lactis NZ3900, and the expression of the exogenous gene and the combination of expression protein and host cell walls can be realized by induction of nisin. The carrier can be used for expressing foreign proteins including vaccine antigens and has a wide application range.

The invention discloses a method of extracting and preparing lysine sulphate from a fermenting liquid containing lysine. The method comprises micro-filtering the fermenting liquid containing lysine to remove thallus, decoloring and removing impurities by using a nanofiltration membrane, performing ion exchange by using a destaining solution to remove ions and ash content, concentrating, acidifying, cooling, crystallizing and drying an ion exchange liquid to obtain high-purity lysine sulphate with purity of being more than 98.5%. 65% of lysine sulphate is prepared by concentrating, spraying and drying after membrane dense phase and crystallization mother liquor are mixed. The lysine sulphate prepared by the method has the advantages of high yield, high product purity, simple process, simple operation and less environmental pollution.

The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).

(Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same.(Means for Solving Problems)The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.

The invention relates to the technical field of gene engineering, in particular to novel broad-spectrum chimeric lysin BGS-PlySb and an encoding gene and application thereof. The novel broad-spectrum chimeric lysin BGS-PlySb has an amino acid sequence shown as in SEQ ID NO. 1; the encoding gene of the novel broad-spectrum chimeric lysin BGS-PlySb has a nucleotide sequence shown as in SEQ ID NO. 2. A novel chimeric lysin is constructed by means of gene splicing and is suitable for killing various species of Streptococcus and Staphylococcus, particularly various species of Enterococcus, and Staphylococcus aureus, as well as Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus suis, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus mutans, Streptococcus iniae and other species; the novel broad-spectrum chimeric lysin BGS-PlySb has good stability and is insensitive to high-concentration NaCl, recombinant protein GBS-PlySb is well expressible in Escherichia coli BL21 (DE3), and a high dose of GBS-PlySb is free of significant cytotoxicity. Therefore, the novel broad-spectrum chimeric lysin BGS-PlySb is applicable independently to or as an additive to the control of various species of Streptococcus and the treatment of infections caused by these species, and has a promising application prospect.

The invention discloses a bacteriophage lysin with animproved antibacterial effect. The 99th leucine and the 102nd methionine of lyase Bp7e amino acid are respectively mutated to obtain alanine and glutamic acid, by using a prokaryotic expression technique, mutant protein can be obtained, and the mutant protein is identified by using Western-blot and is named Bp7c mutant protein. Bp7e and Bp7e mutant protein are purified, the concentration of Bp7e and Bp7e mutant protein is detected, and the in-vitro pyrolysis experiment and the pyrolysis spectrum detection show that purified Bp7e and Bp7e mutant protein have a broad-spectrum antibacterial function and have pyrolysis effects on micrococcus lysodeikticus, staphylococcus aureus, salmonellae and multiple serotype escherichia colis, and the pyrolysis effect of the Bp7e mutant protein is wholly superior to that of natural lyase Bp7e.

The invention provides a purification method of a recombinant human tissue type profibrinolysin activator modified body (rhM-tPA). The method sequentially comprises the following steps of: supernatant fluid filtration processing, first chromatography purification processing, second chromatography purification processing, third chromatography purification processing and fourth ultrafiltration concentration processing. The method obtains a finished rhM-tPA product by carrying out three chromatography purification processings on the recombinant human tissue typ profibrinolysin activator modified body (rhM-tPA) in a bioreactor, wherein the first chromatography purification processing adopts Blue SepharoseTM 6 Fast Flow affinity column ladder shape eluting; the second chromatography purification processing adopts Zn 2+-POROS 20 MC chelating column chromatography; and the third chromatography purification processing adopts Biosepra Lysin Hyperd affinity column chromatography. The three chromatography purification processings all adopt the affinity chromatography, and a needed finished rhM-tPA product with high purity and activity can be obtained only by simply processing the supernatant fluid obtained by filtration processing. The method has simple and convenient operation, low cost and greater economic benefits.

General methods and strains of bacteria are described, that dramatically simplify and streamline plasmid DNA production. In one preferred embodiment, endolysin mediated plasmid extraction combined with flocculation mediated removal of cell debris and host nucleic acids achieves increased yield and purity with simplified downstream purification and reduced waste streams, thus reducing production costs.

The present invention relates to novel polypeptides derived from endolysins from a bacteriophage of Clostridium perfringens and to nucleic acid molecules encoding the same, as well as compositions thereof. The invention also provides uses of such polypeptides and nucleic acid molecules in the diagnosis and treatment of conditions and diseases associated with microbial cells such as Clostridium perfringens. In particular, the invention provides a polypeptide having endolysin activity derived from bacteriophage ΦCP51 of Clostridium perfringens and uses thereof.

The invention relates to the technical field of molecular biology, in particular to preparation and application of mycobacteriophage lyase Lysin-Guo1. The invention provides the preparation and application of the mycobacteriophage lyase. The invention provides a bacteriostatic agent; the bacteriostatic agent is prepared from main active components selected from at least one of the mycobacteriophage lyase Lysin-Guo1, a carrier containing a Lysin-Guo1 expression element, an expression cassette containing a Lysin-Guo1 expression element, or host cells containing Lysin-Guo1 expression elements; the Lysin-Guo1 has an amino acid sequence shown in SEQ ID No 1. The invention also provides a preparation method of the mycobacteriophage lyase Lysin-Guo1. The mycobacteriophage lyase Lysin-Guo1 is capable of cleaving multiple types of mycobacterium tuberculosis, and is also found to have a certain inhibiting effect on other bacteria including escherichia coli, staphylococcus aureus, acinetobacter baumannii and pseudomonas aeruginosa. The preparation and application of the mycobacteriophage lyase Lysin-Guo1 lay a foundation for anti-tuberculosis substitution therapy of drug-resistant tuberculousbacillus.

Granulysin peptides are small antimicrobial agents with potent activity against bacteria and inflammation. A pharmaceutical composition comprising granulysin peptides as an active agent is administered therapeutically to a patient suffering from a microbial infection.